Skip to main content Skip to main navigation menu Skip to site footer

Antiproliferation and Apoptosis Effect of Cisplatin and Nanocurcumin on Ovarian Cancer SKOV3 Cell

  • Sigit Purbadi ,
  • Muhammad Yusuf ,
  • Wawaimuli Arozal ,
  • Aroem Naroeni ,
  • Hariyono Winarto ,
  • Andi Darma Putra ,
  • Gilbert Elia Sotarduga ,

Abstract

Background: Ovarian cancer is one of the leading cancers in women. Seventy percent were founded in the advanced stage, with a 5-year survival rate of only 46%. The current treatment modality is cytoreduction with platinum-based adjuvant chemotherapy as the first line. The effectiveness of chemotherapy is only 60% in the advanced stage, later developing into recurrent. Therefore, additional types of therapy are required based on agents that work specifically in cancer cells and synergize with current standard treatments. This study aimed to know the anti-proliferation effect and apoptosis effect of combination cisplatin with nanocurcumin on SKOV3 cells.

Methods: This experimental study was conducted in vitro using the biological cell line SKOV3 to determine the anti-proliferation effect (expression Ki67) and the apoptosis effect (caspase 3 and 8) of combination cisplatin with combination with cisplatin nanocurcumin on the cell. The data were analyzed with unpaired T when regular distribution / Mann Whitney test when the distribution is abnormal and using Graph Pad Prism.

Results: Based on this result, 50cc of nanocurcumin is 67 μm, and 50cc of cisplatin is 54 μm, using the MTT Assay method. The viability of the cells in this study decreased according to the dose-dependent, whereas the combined dose of 134 μm nanocurcumin with 108 μm cisplatin found the lowest life cell, 24.3% (p <0.001). Ki67 expression was low in the SKOV3 cells post-exposure to cisplatin, but increased post-exposure to nanocurcumin, suspected nanocurcumin at certain doses of pro-oxidant properties that triggered proliferation. Caspase 3 and 8 cannot be detected in this cell by the ELISA method.

Conclusions: Nanocurcumin has a potential effect on chemosensitive cells. However, our study shows no healing effect in chemoresistance cells, particularly SKOV3.

References

  1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. International Journal of Cancer. 2019 Apr 15;144(8). https://doi.org/10.1002/ijc.31937
  2. Aziz MF. Gynecological cancer in Indonesia. Journal of Gynecologic Oncology. 2009;20(1). https://doi.org/10.3802/jgo.2009.20.1.8
  3. Indonesian Society of Gynecology Oncology. INASGO - Cancer Registration National Data 2020 [Internet]. 2020 [cited 2021 Sep 7]. Available from: http://inasgo.org
  4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021 May 4;71(3). https://doi.org/10.3322/caac.21660
  5. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-Year Relative Survival for Epithelial Ovarian Cancer. Obstetrics & Gynecology. 2012 Sep;120(3). https://doi.org/10.1097/AOG.0b013e318264f794
  6. Cristea M, Han E, Salmon L, Morgan RJ. Review: Practical considerations in ovarian cancer chemotherapy. Therapeutic Advances in Medical Oncology. 2010 May 12;2(3). https://doi.org/10.1177/1758834010361333
  7. Colombo N, Lorusso D, Scollo P. Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future. International Journal of Gynecologic Cancer. 2017 Jul 1;27(6). http://dx.doi.org/10.1097/IGC.0000000000001023
  8. Timmermans M, Sonke GS, van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. European Journal of Cancer. 2018 Jan;88. https://doi.org/10.1016/j.ejca.2017.10.030
  9. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. CURCUMIN: THE INDIAN SOLID GOLD. In: The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease. Boston, MA: Springer US; https://doi.org/10.1007/978-0-387-46401-5_1
  10. Gonera A, Wawryka J, Sobkowicz A, Biezunska-Kusiak K, Dubinska-Magiera M, Krajewski A, et al. SKOV-3 and Me45 cell response to cisplatin-based chemotherapy: an in vitro study. Folia biologica. 2014;60(5). PMID: 25863038
  11. Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, et al. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. European Journal of Cancer. 2013 Jan;49(2). https://doi.org/10.1016/j.ejca.2012.06.026
  12. van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-Related Cancer. 2018 May;25(5). https://doi.org/10.1530/ERC-17-0336
  13. Vallianou NG, Evangelopoulos A, Schizas N, Kazazis C. Potential anticancer properties and mechanisms of action of curcumin. Anticancer research. 2015;35(2). PMID: 25667441
  14. Deng J, Wang L, Chen H, Hao J, Ni J, Chang L, et al. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget. 2016 Aug 23;7(34). https://doi.org/10.18632/oncotarget.9908
  15. Kurman R, Scully R. Clear cell carcinoma of the endometrium. An analysis of 21 cases. Cancer. 1976;37(2):872-882. https://doi.org/10.1002/1097-0142(197602)37:2<872::AID-CNCR2820370236>3.0.CO;2-L
  16. Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, et al. Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels. Cancer Research. 2017 May 15;77(10). https://doi.org/10.1158/0008-5472.CAN-16-0707
  17. Notoya M, Nishimura H, Woo J-T, Nagai K, Ishihara Y, Hagiwara H. Curcumin inhibits the proliferation and mineralization of cultured osteoblasts. European Journal of Pharmacology. 2006 Mar;534(1–3). https://doi.org/10.1016/j.ejphar.2006.01.028
  18. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochemical Pharmacology. 2005 Sep;70(5). https://doi.org/10.1016/j.bcp.2005.04.043
  19. Singh AK, Sidhu GS, Deepa T, Maheshwari RK. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Letters. 1996 Oct;107(1). https://doi.org/10.1016/0304-3835(96)04357-1
  20. Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, et al. Role of the NFκB-signaling pathway in cancer. OncoTargets and Therapy. 2018 Apr;Volume 11. https://doi.org/10.2147/ott.s161109
  21. Sahebkar A, Cicero AFG, Simental-Mendía LE, Aggarwal BB, Gupta SC. Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. Pharmacological Research. 2016 May;107. https://doi.org/10.1016/j.phrs.2016.03.026

How to Cite

Purbadi, S., Yusuf, M., Arozal, W., Naroeni, A., Winarto, H., Putra, A. D., & Sotarduga, G. E. (2022). Antiproliferation and Apoptosis Effect of Cisplatin and Nanocurcumin on Ovarian Cancer SKOV3 Cell. Bali Medical Journal, 11(1), 377–381. https://doi.org/10.15562/bmj.v11i1.2937

HTML
0

Total
0

Share

Search Panel